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Abstract 
This study aims to assess the pharmacological effects of aqueous extract roots of Rauwolfia vomitoria (EARv), a 
plant used in traditional medicine in the Ivory Coast to treat diabetes, on blood glucose normoglycemic rats and 
on glucose tolerance in rats by administration of glucose. The acute toxicity, as well as the phytochemicals 
present in this extract is also determined. During the experience, fives groups of rats received respectively 
distilled water, EARv at doses of 500, 700 and 1000 mg/kg of body weight and 10 mg/kg of glibenclamide. 
Then the blood glucose level of each rat was measured using a glucometer. Hyperglycemia was induced in rats 
by oral administration of glucose at dose of 4 g/kg. The rats were pretreated or post-treated of the same doses of 
tests substances and blood glucose level of each rat was measured. Acute toxicity by oral administration was 
studied in mice and phytochemical screening was performed by thin layer chromatography. The results show 
that EARv administered orally at doses up to 5000 mg/kg B.W., does not cause the death of the treated mice.  
------------------------------------------------------------------------ 
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At 500, 700 and 1000 mg/ kg B.W., EARv causes, like glibenclamide at 10 mg/kg B.W., a reduction of blood 
glucose level of treated normoglycemic rats. In addition, EARv at 1000 mg/kg B.W. reduced and quickly 
nullifies the glucose tolerance in rats that is induced by oral administration of glucose (4 g/kg B.W.). This effect 
is also observed with glibenclamide (10 mg/kg B.W.). The phytochemical screening shows that EARv contains 
alkaloids, flavonoids, and antrhones and anthraquinones, catechin tannins, saponins and monoterpenoids. This 
study shows that the aqueous extract of Rauwolfia vomitoria has hypoglycemic and some antihyperglycemic 
properties, that justify its use in the treatment of diabetic hyperglycemia in traditional medicine. 
Keywords: Rauwofia vomitoria; diabetes; hypoglycemia; anti-hyperglycemia. 
1. Introduction 
Diabetes mellitus is a metabolic disorder characterized by chronically elevated blood glucose level linked to a 
deficiency to either insulin secretion or action of insulin [1, 2]. It is responsible for many complications during 
its evolution [3, 4]. The prevalence of diabetes is evolving exponentially worldwide and in particular in black 
Africa where over 20 million people are affected [5]. In the Ivory Coast, according to the International Diabetes 
Federation (IDF), there were 490200 cases of diabetes in 2014, 5.6 % of adult population with ages between 20 
and 79 years [6]. The different drugs used for the treatment of diabetes mellitus, are not always accessible to the 
population, particularly African. In addition, the drugs showed their limitations given the growing prevalence of 
diabetes. Even today, these people continue to heal with herbal medicines for the treatment of diabetes mellitus 
and various other pathologies. 
In Ivory Coast, various plants used in traditional medicine for the treatment of diabetes mellitus were listed [7]. 
Rauvolfia vomitoria (Apocynaceae) is also used to treat this disease.  It is also used in Ivory Coast for the 
treatment of fever and infections moisture [8]. Previous work revealed that (70 %) ethanolic extract of root 
without bark of Rauvolfia vomitoria induced a hypoglycaemic effect in normoglycemic rats and an 
antihyperglycemic effect in rats submitted glucose tolerance test [9]. 
  This study aims to assess the effects of an aqueous extract of roots without bark of Rauwolfia vomitoria on 
blood glucose normoglycemic rats and on glucose tolerance in rats by administration of glucose, and to 
determine the toxicity and phytochemicals of this extract. 
2. Materials and methods 
2.1. Biological materiel 
2.1.1. Plant materiel 
The plant material used consists of boots roots of Rauwolfia vomitoria Afzel. (Apocynaceae) obtained in the 
markets of medicinal plants in Abidjan.   
2.1.2. Animals 
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White rats of the species Rattus norvegicus (Muridae), the mass of which is between 120 and 150 g, are used for 
blood glucose studies. Mouse, Mus musculus (Muridae), whose mass is between 20 and 25 g were used for the 
acute toxicity study. These animals were nursed in the animal physiology laboratory, pharmacology and 
pharmacopoeia of the Faculty of Natural Sciences of the University Nangui Abrogoua (Abidjan, Ivory Coast) at 
25 °C, and under the light day and the darkness night. They were fed with animal food provided by the company 
IVOGRAIN® Abidjan (Ivory Coast) and have access to water. 
2.2. Preparation of the aqueous extract of Rauwolfia vomitoria 
The roots of Rauwolfia vomitoria (Apocynaceae) are stripped of their bark and dried at room temperature. They 
are then ground into a fine powder using a grinder. Two hundred grams (200 g) of this powder are mixed with 
two liters (2 L) of distilled water. The mixture was stirred for 24 hours at room temperature, using a magnetic 
stirrer. The macerated product is filtered three times on absorbent cotton, and then with filter paper (Whatman  
n°1 and oven dried at 40 °C. The powder obtained is the aqueous extract of Rauwolfia vomitoria (EARv). 
2.3 Acute toxicity  
50 mice were divided into 10 groups of 5 mice. each mouse of the 9 test batches receive orally 1 ml of a single 
dose of 5, 50, 100, 300, 1000, 2000, 3000, 4000 or 5000 mg / kg body weight (B.W.) of the aqueous extract R. 
vomitoria. Control group received 1 ml (10 ml/kg B.W.) of distilled water. The number of dead mice was 
recorded 48 hours after administration of the substance. This study is performed 3 times. 
2.4. Activity of aqueous extract of Rauwolfia vomitoria roots (EARv) on rat's blood glucose level 
 Blood glucose level of the rats was measured using a brand Accu-Cheikh Active (Roche) and test strips. The 
rats were previously fasted for 12 hours. Their different substances were administered orally. 
2.4.1. Effects of EARv on blood glucose level of normoglycemic rats 
25 rats were used. They are divided into 5 groups of 5 rats. 
- Batch 1: normal glycemic control rats receiving distilled water (10 ml/kg B.W.). 
- Batch 2: EARv treated rats with 500 mg / kg B.W. 
- Batch 3: EARv treated rats with 700 mg / kg B.W. 
- Batch 4: EARv treated rats with 1000 mg / kg B.W. 
- Batch 5: rats treated with glibenclamide (reference material) with 10 mg / kg B.W. 
Blood glucose is first determined just prior to treatment; it is the initial blood glucose (t0). After the treatment of 
animals, blood glucose was measured every 30 minutes for 2 hours, and the percent change of blood glucose 
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level is calculated with respect to the initial glucose. 
2.4.2. Effects of EARv during glucose tolerance test 
Hyperglycemia was induced in rats by oral administration of glucose at a dose of 4 g/kg B.W. 
2.4.2.1. Testing blood glucose in hyperglycemic rats pretreated   
 30 rats were divided into 6 groups of 5 rats. 
- Batch 1: negative control rats receiving distilled water (10 ml/kg B.W.) only. 
- Batch 2: positive control rats receiving distilled water (10 ml/kg B.W.), and 30 minutes later, 4 g/kg B.W. of 
glucose  
- Batch 3: rats receiving 500 mg/kg of EARv B.W., then 4 g/kg B.W. of glucose 30 minutes after. 
- Lot 4: rats receiving 700 mg/kg B.W. EARv, then 4 g/kg B.W. of glucose 30 minutes after.  
Lot 5: rats receiving 1000 mg/kg B.W. of EARv, then 4 g/kg B.W. of glucose 30 minutes after. 
- Lot 6: Rats receiving glibenclamide (10 mg/kg B.W.), and then 4 g/kg of glucose B. W. 30 minutes later. 
Blood glucose level of rats of each batch was measured just before administration of substances or distilled 
water and after treatment, at intervals of 30 minutes, 2 hours and 30 minutes. The percentage increase in blood 
glucose level and the percentage reduction in glucose tolerance were calculated. 
2.4.2.2. Testing blood glucose in post-hyperglycemic rats treated with EARv 
The protocol was the same as for pretreated rats. However, in this series of experiments, different batches of rats 
receive doses EARv tests (500, 700 and 1000 mg/kg B.W.) or glibenclamide (10 mg/kg W.B.) 30 minutes after 
induction of hyperglycemia by oral administration of 4 g/kg glucose PC. Glucose of the rats of each batch was 
measured just before the glucose administration and thereafter at intervals of 30 minutes for 2 hours and 30 
minutes. The percentage increase in blood glucose and the percentage reduction in glucose tolerance were also 
calculated. 
2.5. Phytochemical screening 
The detection of secondary metabolites in the aqueous extract of Rauwolfia vomitoria was performed with the 
technique of thin layer chromatography. To do this, ten (10) µL of EARv were placed on chromatographic 
plates (aluminum sheets coated with silica gel 60 F254 with a thickness of 0.2 mm, Merck). The eluent is 
composed of chloroform: methanol: water (65: 35: 5). After drying, the chromatograms were revealed with 
suitable reagents [10] and were observed in visible light, or under UV light at 254 nm or 366 nm. 
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2.6. Statistical analysis and plotted graphs 
Data analysis was done using the software GraphPad INSTAT (San Diego CA USA). Means and standard errors 
of the means (M ± SEM) were comuted. The difference between two means was evaluated with the test of 
Student-Newman-Keuls at the level of α = 0.05. GraphPad Prism software (San Diego CA USA) was used to 
draw the graphs. 
3. Results 
3.1. Acute toxicity   
The Rauwolfia vomitoria aqueous extract (EARv) administered orally at doses lower than or equal to 5000 
mg/kg B.W., causes no mortality in the treated mice. 
3.2. Effect of aqueous extract on blood glucose normoglycemic rats and hyperglycemic rats 
3.2.1. Dose-response effects of aqueous extract (EARv) and glibenclamide on glucose normoglycemic rats 
Changes of blood glucose level in rats after oral administration of  EARv at 500, 700 and 1000 mg / kg B.W., or 
glibenclamide at a dose of 10 mg/kg B. W. are shown in Figure 1. Blood glucose of control rats who received 
only distilled water, did not vary significantly (p > 0.05) throughout the duration of the study (2 hours). It was 
maintained at 0.97 ± 0.04 g/L. EARv at doses of 500, 700 and 1000 mg/kg B.W., induces a dose-dependent 
reduction in blood glucose treated rats. These reductions were significant (p < 0.05) 30 minutes after treatment 
rats. These hypoglycemia gradually increased over time and 120 minutes after treatment, blood glucose level 
reductions were 0.18 ± 0.01 g/L, 0.24 ± 0.02 g/L and 0.30 ± 0.03 g/L, respectively for EARv doses of 500, 700 
and 1000 mg/kg B.W., with respective rates of 18.37 % blood glucose reduction, 24.24 % and 30.30 % (p < 
0.001). Glibenclamide (reference substance), administered at a dose of 10 mg / kg B.W., also significantly 
decreased blood glucose level (p < 0.01) 30 minutes after the treatment of the rats and progressively with time. 
120 minutes after the treatment of rats, the decrease of blood glucose was 0.32 g/L, with blood glucose 
reduction rate of 32.59 (p <0.001). The effects of glibenclamide at a dose of 10 mg / kg body weight were more 
significant than EARv at doses of 500 and 700 mg/kg B.W. However, its effects were not statistically different 
to those of EARv the dose of 1000 mg/kg B.W. (p > 0.05). 
3.2.2. Effects of aqueous extract (EARv) and glibenclamide on induced hyperglycemia in rats 
3.2.2.1. Change in blood glucose levels in hyperglycemic rats pretreated with EARv or glibenclamide 
The results of this study are presented in Figure 2. Glucose of the negative control group consisting of rats given 
only distilled water, did not vary significantly (p> 0.05) throughout the 3 hours of experimentation. It was of the 
order of 0.98 ± 0.03 g/L. 
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Figure 1: Dose response effects of aqueous extract of Rauwolfia vomitoria (EARv) and glibenclamide on 
glucose normoglycemic rats 
Oral administration of glucose at a dose of 4 g/kg B.W. into rats that received or not, 30 minutes before, EARv 
(500, 700 and 1000 mg/kg B.W.) or glibenclamide (10 mg/kg B.W.) causes an increase in blood sugar of the 
animals. However, the peak hyperglycemia that occurred 30 minutes after administration of glucose varied 
depending on whether the rats were pretreated or not with EARv or glibenclamide. During the first 30 minutes 
after treatment, blood glucose of rats receiving different doses of EARv or glibenclamide did not vary 
significantly (p > 0.05). 
In positive control rats (hyperglycemic control), the glucose administration results in an increase of blood 
glucose, with glucose tolerance peak of the order of 0.53 ± 0.02 g/L. Thereafter, this hyperglycemia is gradually 
reduced and the basal blood glucose was found 2 hours 30 minutes after the glucose administration. EARv at 
doses of 500, 700 and 1000 mg/kg B.W., resulted in significant decreases (p < 0.001) and dose-dependent 
induced hyperglycemia following administration of glucose. For these doses EARv the hyperglycemia peaks 
were respectively 0.40 ± 0.06 g/L, 0.34 ± 0.05 g/L and 0.30 ± 0.03 g/L; corresponding to 24.53 %, 35.85 % and 
43.40 % reduction of the induced hyperglycemia, compared to the positive control. These highs are gradually 
reduced over time. Thus, in the presence of EARv at a dose of 500 mg / kg B.W., the initial blood sugar was 
found 2 hours 15 minutes after the administration of glucose and thereafter the hypoglycemia estimated at 0.04 
g/L was not significant hypoglycemia (p> 0.05). When the rats were pretreated with EARv at doses of 700 and 
1000 mg / kg BW, hyperglycemia induced by glucose are gradually reduced over time and the initial blood 
sugar was attained, respectively, 1 hour 45 minutes and 1 hour 38 minutes after the glucose administration. 
However, hypoglycemia subsequently increased to significant levels with concentrations of 0.19 g/L (p < 0.05) 
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and 0.28 g/L (p < 0.001) respectively. Glibenclamide, in the dose of 10 mg / kg B.W., significantly reduced (p < 
0.001) induced hyperglycemia by the administration of glucose. The hyperglycemia peak was 0.27 ± 0.04 g/L, 
corresponding to 49.06 % in reductions of hyperglycemia induced by glucose. This hyperglycemia was then 
gradually reduced and the initial blood glucose was attained 1 hour 30 minutes after the glucose administration. 
A significant hypoglycemia (p < 0.001) also followed to reach a concentration of 0.33 g/L. 
Rate reduction hyperglycemia induced by glucose as function of time in rats pretreated with EARv or with 
glibenclamide are shown in Table 1. 
Table 1: hyperglycemia Reduction rate of glucose-induced in rats pretreated with (EARv) or glibenclamide 
 Time after administration of glucose 
30 min    60 min   90 min   120 min     150 
min 
 
 
reduction 
induced 
hyperglycemia 
glucose in the 
dose of 4 g / kg B.W. 
(%) 
H2O  
(hyperglycemic 
control) 
0 19,01 34,22 55,13 98,86 
EARv 
(500 mg/kg B.W.) 
23,95 45,63 66,92 95,05 112,17 
EARv              
(700 mg/kg B.W.) 
35,74 58,93 80,23 119,39 132,70 
EARv 
(1000 mg/kg B.W.) 
42,96 63,88 94,29 130,42 153,23 
Glibenclamide  
(10 mg/kg B.W.) 
48,67 74,52 105,70 139,92 162,73 
 
3.2.2.2. Change in blood glucose levels in hyperglycemic rats post-treated with (EARv) or glibenclamide 
Glucose rats constituting the negative control group (rats given only distilled water) did not vary significantly 
during the 3 hours of experimentation (p> 0.05). It is of the order of 0.96 ± 0.03 g / L. 
The administration of glucose at a dose of 4 g/kg in rats P.C. causes hyperglycemia whose peak, which occurs 
30 minutes after gavage, is 0.52 ± 0.02 g/L (Figure 3). The administration or not of tests doses of the aqueous 
extract (500, 700 and 1000 mg/kg B.W.) or glibenclamide (10 mg/kg B.W.) causes a gradual reduction in 
hyperglycemia, and return time to the initial blood glucose varied depending on the substance or the dose 
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administered. Table 2 shows the percentage reduction of the hyperglycemia induced by glucose in post-rats 
treated or not with different doses of EARv or with glibenclamide. 
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Figure 2: Evolution with time of blood glucose levels in hyperglycemic rats pretreated with the aqueous extract 
of Rauwolfia vomitoria (EARv) or glibenclamide 
In positive control Rats (hyperglycemic witnesses), the initial blood glucose level was attained 2 hours and 30 
minutes after the administration of glucose. 
In rats post-treated with different doses of EARv, reducing hyperglycemia and time to reach to the initial 
glucose levels were found to be dose-dependent. Indeed, in rats treated with EARv at doses of 500, 700 and 
1000 mg/kg B.W., the time to reach the initial blood glucose level was 150, 130 and 115 minutes respectively 
and hypoglycemia subsequently occurred at the respective concentrations of 0.10 (p < 0.01), 0.20 (p < 0.01) and 
0.26 g/L (p < 0.001). 
Also, glibenclamide (10 mg/kg B.W.), administered to rats 30 minutes after that of glucose results in greater 
reduction of induced hyperglycemia and initial blood glucose was found at 105 minutes after the glucose 
administration. Subsequently, hypoglycemia occurred with 0.29 g/L (p < 0.001). 
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Table 2: hyperglycemia Reduction rate of glucose-induced in rats post-treated with (EARv) or glibenclamide 
 Times after administration of glucose 
30 min 60 min 90 min 120 min 150 min 180 min 
 
 
reduction 
induced 
hyperglycemia 
glucose in the 
dose of 4 g / kg B.W. 
(%) 
H2O 
(hyperglycemic 
control ) 
0 18 34,8 60,8 95,2 100,8 
EARv 
(500 mg/kg B.W.) 
0 19,54 46,36 82,76 101,91 119,92 
EARv 
(700 mg/kg B.W.) 
0 32,81 61,39 96,52 121,61 138,61 
EARv 
(1000 mg/kg B.W.) 
0 37,31 70,52 110,07 135,44 148,88 
Glibenclamide 
(10 mg/kg B.W.) 
0 41,13 84,15 126,41 146,03 154,7 
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Figure 3: Evolution with time of blood glucose levels in hyperglycemic rats post-treated with aqueous extract 
of Rauvolfia vomitoria (EARv) or glibenclamide 
3.3. Phytochemical screening 
Performed Thin Layer Chromatography revealed the presence of polyphenols, monoterpenoids, flavonoids, 
anthraquinones and anthrones, alkaloids, tannins catechin and saponins in the aqueous extract of Rauvolfia 
vomitoria. 
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4. Discussion 
Aqueous extract of Rauvolfia vomitoria administered orally at doses up to 5000 mg/kg B.W., did not result in 
the death mice. This indicates that the 50 % lethal dose (LD50) of EARv was above 5000 mg/kg B.W., so that 
this extract is non-toxic when administered orally [11]. These results corroborate those of Amole et al. [12] and 
N'Doua et al. [9] which respectively have shown that the aqueous extract of the leaves of Rauvolfia vomitoria 
and (70 %) ethanolic root extract of this plant are not toxic when taken orally. 
Aqueous extract of Rauvolfia vomitoria the, at doses of 500, 700 and 1000 mg/kg B.W., caused dose-dependent 
reduction in blood glucose level normoglycemic rats. It also vginduced the reduction of hyperglycemia caused 
by oral administration of glucose in rats in treatment and in rats post-treated with the extract. This indicates that 
Rauvolfia vomitoria was hypoglycemic and antihyperglycemic. these properties of Rauvofia vomitoria were also 
revealed with (70 %) ethanolic extract of root of this plant [9]. However, the aqueous extract of Rauvofia 
vomitoria is more active than the (70 %) ethanol extract and the effects of the aqueous extract at a dose of 1000 
mg/kg B.W.  were substantially identical with those of glibenclamide at a dose of 10 mg/kg B.W. Glibenclamide 
is a substance belonging to the sulfonamide, recognized for their hypoglycemic and antihyperglycemic activities 
[9, 13, 14, 15]. Sulfonylureas cause hypoglycemia in normoglycemic rats by stimulating the production of 
insulin by the pancreatic beta cells, which promotes the storage of glycogen in the liver [16, 17, 18, 19]. The 
decrease of hyperglycemia induced rats treated with EARv could be explained by the stimulation of insulin 
secretion by the pancreas and/or, possibly, by an increase in peripheral glucose utilization in the presence of 
extract. 
The presence of substances such as flavonoids, polyphenols, saponins and catechin tannin in the Rauvolfia 
vomitoria aqueous extract are the cause of the observed hypoglycemic and anti-hyperglycemic effects. Indeed, 
hypoglycemic and anti-hyperglycemic properties of these secondary metabolites have been reported by several 
authors [20, 21, 22]. 
5. Conclusion 
This study shows that the aqueous extract of roots without bark Rauvolfia vomitoria is non-toxic when taken 
orally and has a high potential hypoglycemic and anti-hyperglycemic substance. These properties of the aqueous 
extract of Rauwolfia vomitoria justify the use of this plant in traditional medicine in the treatment of diabetic 
hyperglycemia. 
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